Ningbo Menovo Pharmaceutical

What Ningbo Menovo Pharmaceutical does

Ningbo Menovo Pharmaceutical (宁波美诺华药业股份有限公司) is a vertically integrated pharmaceutical manufacturer founded in 2004 and listed on the Shanghai Stock Exchange (603538) since April 2017. The company operates an 'API + Formulation' integrated business model spanning pharmaceutical intermediates, active pharmaceutical ingredients (APIs), finished dosage formulations (tablets, capsules, oral solutions), and CMO/CDMO contract manufacturing services. Its product portfolio covers cardiovascular (Olmesartan, Irbesartan, Perindopril, Clopidogrel, Apixaban), diabetes (Empagliflozin, Vildagliptin, Sitagliptin/Metformin), neuropsychiatric (Duloxetine, Mirtazapine), respiratory, anti-infective (Moxifloxacin), and hepatology (Tenofovir Alafenamide) therapeutic areas, with both domestic distribution through China's national centralized procurement (集采) program and global exports to Europe, the US, Japan, and Southeast Asia.

The company's technical foundation rests on continuous flow microreactor green manufacturing technology, advanced QC infrastructure (nearly 200-person testing team with LC-MS, GC-MS, HPLC instrumentation), and Six Innovation Platforms covering small nucleic acid, PROTAC, complex injection, specialty medication, synthetic biology, and drug registration capabilities. Manufacturing is distributed across multiple subsidiaries: Anhui Menovo (Guangde, ~145,000 sqm), Zhejiang Menovo (Shangyu R&D Center with 140+ professionals and 6 PhDs), Ningbo Menovo Tiankang (Dahe, ~56,000 sqm formulation platform with 1.5B tablets/capsules capacity expanding to ~7.5B), Xuancheng Menovo (~150,000 sqm API manufacturing), and international presence via Biomenovo Research (India), Hong Kong trading arm, and US subsidiary. The company holds EU GMP certifications (2008-2017), US FDA and Japan PMDA approvals via Liaoyuan Pharmaceutical, plus ISO 14001 environmental certification.

Revenue is generated through four streams: (1) API sales to global generic and innovative drug developers, (2) formulation sales domestically via centralized procurement and direct channels, (3) intermediate manufacturing for API producers, and (4) CMO/CDMO contract manufacturing services. The company maintains a sales-led go-to-market model with dedicated direct sales presence in China and Europe, supported by Ningbo Lianhua Import & Export for international trade and participation in CPhI/API exhibitions globally. Government engagement is significant, including a National Medical Insurance Bureau visit in December 2025, reflecting the company's alignment with national pharmaceutical policy priorities including volume-based procurement programs.

Name

Ningbo Menovo Pharmaceutical

Legal name

宁波美诺华药业股份有限公司

Website

https://menovopharm.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Ningbo Menovo Pharmaceutical is a Chinese vertically integrated pharmaceutical manufacturer (API + Formulation) producing intermediates, APIs, and finished dosage forms across cardiovascular, diabetes, neuropsychiatric, and other therapeutic areas, serving global generic and innovative drug developers plus domestic healthcare providers through national centralized procurement.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical formulation manufacturing
• Pharmaceutical intermediates
• Contract manufacturing services
• Cardiovascular diabetes therapeutics

Headquarters

HQ city

Ningbo

HQ country

China

HQ region

Asia

Offices12 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. API Sales (原料药): Manufacturing and sale of active pharmaceutical ingredients (APIs) for cardiovascular, diabetes, gastrointestinal, psychiatric, and anti-tumor therapeutic areas. APIs are supplied domestically and exported globally to original drug developers and generic drug manufacturers.
2. Formulation/Finished Drug Sales (制剂): Production and sale of finished dosage forms (tablets, capsules, oral solutions) covering cardiovascular, diabetes, respiratory, neurological, anti-coagulation, bone/joint, anti-infective, and hepatology therapeutic areas. Products sold domestically and to European markets.
3. Intermediates (中间体): Manufacturing and sale of pharmaceutical intermediates for a wide range of APIs including statins, ACE inhibitors, and other cardiovascular drugs.
4. CMO/CDMO Contract Manufacturing (合同定制): Custom synthesis and contract manufacturing services for pharmaceutical intermediates and APIs, providing comprehensive API solutions to downstream formulation customers. CMO/CDMO services for external pharmaceutical companies.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Ningbo Menovo Pharmaceutical manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical intermediates, finished dosage formulations (tablets, capsules, oral solutions), and provides CMO/CDMO contract manufacturing services. The integrated 'API + Formulation' model spans cardiovascular, diabetes, neuropsychiatric, respiratory, anti-coagulation, anti-infective, hepatology, and anti-tumor therapeutic areas, with products sold domestically through China's national centralized procurement (集采) program and exported globally to original drug developers and generic manufacturers.

Product overview

Ningbo Menovo Pharmaceutical operates as an integrated pharmaceutical company with four main business segments: 制剂 (Formulations/Finished Dosage Forms), 原料药 (Active Pharmaceutical Ingredients/APIs), 中间体 (Pharmaceutical Intermediates), and 合同定制 (Contract Manufacturing Services). The company has implemented an 'API + Formulation' integration strategy, combining self-developed APIs with finished dosage forms to serve global innovative drug companies and generic drug customers. The product portfolio covers cardiovascular (e.g., 奥美沙坦酯片, 厄贝沙坦片, 培哚普利叔丁胺片), diabetes (e.g., 恩格列净片, 维格列汀片, 西格列汀二甲双胍片), neuropsychiatric (盐酸度洛西汀肠溶胶囊, 米氮平片), respiratory, antiplatelet (硫酸氢氯吡格雷片), and other therapeutic areas. The company is developing six innovation platforms including 小核酸, PROTAC, 复杂注射剂, 特色专科用药, 合成生物学, and 药品持证 to support strategic transformation from generic to innovative drugs.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs / 原料药) Active pharmaceutical ingredients manufactured and supplied in bulk to global generic drug manufacturers and original drug developers across multiple therapeutic categories.
• Finished Dosage Formulations (制剂) Finished dosage forms (tablets, capsules, oral solutions) sold domestically via China's national centralized procurement and exported to European markets, spanning cardiovascular, diabetes, neuropsychiatric, respiratory, anti-coagulation, bone/joint, anti-infective, and hepatology therapies.
• Pharmaceutical Intermediates (中间体) Key intermediate molecules used in the manufacture of statins, ACE inhibitors, and other cardiovascular APIs, manufactured and sold to pharmaceutical companies.
• CMO/CDMO Contract Manufacturing Services (合同定制) Custom synthesis, process development, scale-up, and commercial contract manufacturing of pharmaceutical intermediates and APIs offered to external pharmaceutical companies.
• Olmesartan Medoxomil Tablets (奥美沙坦酯片) Antihypertensive finished dosage formulation for the treatment of hypertension, sold domestically and to European markets.
• Eltrombopag Olamine Tablets (艾曲泊帕乙醇胺片) Thrombopoietin receptor agonist for treatment of chronic immune thrombocytopenia (ITP) in adults and children aged 6+.
• Ambroxol Hydrochloride and Clenbuterol Oral Solution (氨溴特罗口服溶液) Combination oral solution for treatment of acute and chronic respiratory diseases including bronchitis and emphysema.
• Irbesartan Tablets (厄贝沙坦片) Angiotensin II receptor blocker for treatment of essential hypertension and diabetic nephropathy.
• Empagliflozin Tablets (恩格列净片) SGLT2 inhibitor for treatment of type 2 diabetes and symptomatic chronic heart failure.
• Clopidogrel Bisulfate Tablets (硫酸氢氯吡格雷片) Antiplatelet agent for standard antiplatelet therapy, PCI, coronary heart disease, and prevention of myocardial infarction and stroke recurrence.
• Perindopril tert-Butylamine Tablets (培哚普利叔丁胺片) ACE inhibitor for treatment of hypertension and congestive heart failure.
• Apixaban Tablets (阿哌沙班片) Direct oral anticoagulant for prevention of venous thromboembolism (VTE) in adults undergoing hip or knee replacement surgery.
• Duloxetine Hydrochloride Enteric-coated Capsules (盐酸度洛西汀肠溶胶囊) SNRI antidepressant for treatment of major depressive disorder, generalized anxiety disorder, and chronic musculoskeletal pain.
• Vildagliptin Tablets (维格列汀片) DPP-4 inhibitor for treatment of type 2 diabetes as monotherapy or in combination with metformin, insulin, or sulfonylureas.
• Sitagliptin and Metformin Tablets (西格列汀二甲双胍片) Combination DPP-4 inhibitor and biguanide for dietary and exercise therapy in type 2 diabetes patients uncontrolled on metformin monotherapy.
• Tenofovir Alafenamide Fumarate Tablets (富马酸丙酚替诺福韦片) Nucleoside reverse transcriptase inhibitor for treatment of chronic hepatitis B in adults and adolescents aged 12+ (weight ≥35 kg).
• Moxifloxacin Hydrochloride Tablets (盐酸莫西沙星片) Fluoroquinolone antibiotic for treatment of susceptible bacterial infections in adults (≥18 years).
• Mirtazapine Tablets (米氮平片) Noradrenergic and specific serotonergic antidepressant for treatment of depression.

Quantifiable outcome

• Cardiovascular, diabetes, gastrointestinal, psychiatric, anti-tumor core products hold dominant market position in China and are exported globally to multiple countries and regions
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Dubhelion (Malaysia)notableStrategic or Co-development Partner · 1 September 2025Menovo signed a strategic cooperation agreement with Malaysia-based Dubhelion to jointly expand the Southeast Asian cardiovascular and diabetes market. The partnership leverages Menovo's API-formulation integration advantages and Dubhelion's regional market presence.

Scale indicators6 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• CSPC Pharmaceutical Group: One of China's largest pharmaceutical conglomerates spanning APIs, formulations, biologics, and innovative drugs. Comparable as a broader Chinese pharma peer with significantly larger scale across both generic and innovative drug segments than Menovo.

Regional players

• Lupin Limited: Indian generic and specialty pharmaceutical manufacturer with API and finished dosage capabilities serving global markets. Comparable to Menovo on small-molecule API manufacturing scale and US/EU export orientation, though operating from lower-cost India base.
• Aurobindo Pharma: India-based global generic API and finished dosage form manufacturer with major US and European market presence. Comparable to Menovo on small-molecule API export model but operates from a lower-cost Indian manufacturing base, intensifying competitive pressure on Menovo's regulated-market exports.

Direct peers

• Apeloa Pharmaceutical: Chinese API and formulation manufacturer with vertical integration and CDMO capabilities, exporting globally. Comparable to Menovo across API intermediates, finished dosage forms, and CMO/CDMO services in cardiovascular and anti-infective therapeutic areas.
• Zhejiang Medicine: Chinese integrated API and formulation manufacturer serving regulated international markets with cardiovascular, anti-infective, and other therapeutic categories. Comparable to Menovo on integrated business model and international regulatory footprint.
• Zhejiang Hisun Pharmaceutical: Chinese pharmaceutical manufacturer focused on APIs and finished formulations with international regulatory certifications (US FDA, EU GMP, etc.). Direct comparable to Menovo on integrated API-to-formulation operations and export orientation.
• Zhejiang Huahai Pharmaceutical: Leading Chinese integrated API + formulation manufacturer with strong US FDA and EU GMP presence, exporting cardiovascular and other generics globally. Closest comparable to Menovo on integrated small-molecule API-to-finished-drug strategy and international certification footprint.
• Krka: Slovenian generic pharmaceutical company focused on cardiovascular, diabetes, and other chronic disease therapeutics. Already a Menovo JV partner (Ningbo Krka Menovo), making it a natural strategic comparable on generic portfolio composition and international commercialization model.
• Shandong Xinhua Pharmaceutical: One of China's largest API manufacturers with substantial export business and integrated formulation capabilities. Comparable to Menovo across small-molecule API manufacturing scale, export focus, and finished dosage form portfolio.
• Zhejiang Jingxin Pharmaceutical: Chinese pharmaceutical company producing APIs and finished formulations across cardiovascular, neurological, and infectious disease categories. Comparable to Menovo on therapeutic area focus and integrated manufacturing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ningbo-menovo-pharmaceuticals-group-co.-ltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ningbo Menovo Pharmaceutical